Drugs / LY01021
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07236476 | Oct 2024 → Dec 2025 overdue | — | Luye Pharma Group Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY01021 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07236476 ↗ |
| Route | Oral | “taken orally once a day.” NCT07236476 ↗ |